Trump to Ease U.S. Fuel-Economy Standards 
Germany’s 2026 Growth Outlook Strengthens on Fiscal Spending 
Morgan Stanley Raises TD Synnex Price Target to $359 on Strong AI Demand 
Suzuki Targets Faster Car Development to Keep Pace With Chinese Rivals 
OpenAI Investigates Rogue AI Agents After Data Leaks and Security Incidents 
Hong Kong Home Prices Stabilize in August After July Decline 
Almonty Industries Shares Jump 8% After Stifel Sets $25 Target 
UK Housebuilder Stocks Surge on New First-Time Buyer Loan Scheme 
TSMC Accelerates 2nm Expansion as AI Chip Demand Surges 
Oil Prices Fall on U.S.-Iran Hormuz Deal Hopes 
US Stocks Face Jobs, Inflation Test as Fed Rate Hike Bets Rise 
China Cuts Tariffs on U.S. Farm Goods but Excludes Soybeans 
Nvidia China Chip Sales Report Sends Chinese Semiconductor Stocks Lower 
Europe’s AI Data Centre Boom Strengthens Case for Nuclear Power 
Asian Chip Stocks Tumble as OpenAI Safety Pause Sparks AI Growth Concerns 
Australia Budget Deficit Narrows to A$22.3 Billion on Stronger Tax Revenue 
Dubai’s connectivity remains strong in an uncertain world 
Add as a preferred source on Google
LG Chem Ltd. announced it set to buy AVEO Pharmaceuticals for $566 million or $15 per share in full cash. The South Korean chemical company headquartered in Seoul is aiming to purchase a 100% stake in the Boston-based company.
With the acquisition, LG Chem will expand its commercial footprint in the US market for a wide range of oncology therapies. The company also revealed on Tuesday, Oct. 18, that it will also use the deal to branch out to other related fields.
According to The Korea Times, AVEO Pharma developed FOTIVDA prescription medicine made for the treatment of relapsed or refractory advanced renal cell carcinoma (RCC). this drug was only approved in March 2021 by the U.S. Food and Drug Administration (FDA).
LG Chem said that this is the first time that a South Korean company is buying a firm that has been granted approval by the FDA for a new type of drug. As it acquires AVEO, the company is planning to invest in LG Chem Life Science Innovation Center so it can establish a special purpose company for the takeover of the US-based pharma firm.
Moreover, the deal will provide LG Chem’s Life Sciences unit with a commercial presence in the United States. This will also speed up the company’s efforts to deliver its continued growth.
The transaction is expected to close in early 2023, and as with any other buyout deals, this is still subject to customary closing conditions. It should be approved by AVEO’s shareholders and go through regulatory processes.
“With its track record of clinical success, deep pipeline of innovative therapies and continued growth trajectory following the successful commercialization of FOTIVDA, AVEO is the perfect partner for LG Chem Life Sciences,” LG Chem’s chief executive officer, Shin Hak Cheol, said in a press release. “This transaction represents the next step in our portfolio transformation towards higher growth markets and provides a strong commercial foundation in oncology as we continue to develop our anti-cancer offerings.
The CEO further said, “We remain focused on prudently investing in our R&D capabilities, continuing to build a leading portfolio of therapies and transforming lives through inspiring science and leading innovation.”
